Literature DB >> 24452759

Mouse models of prostate cancer: picking the best model for the question.

Magdalena M Grabowska1, David J DeGraff, Xiuping Yu, Ren Jie Jin, Zhenbang Chen, Alexander D Borowsky, Robert J Matusik.   

Abstract

When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for "prostate cancer mouse model" yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?

Entities:  

Mesh:

Year:  2014        PMID: 24452759      PMCID: PMC4108581          DOI: 10.1007/s10555-013-9487-8

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  155 in total

1.  Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer.

Authors:  Y Guo; S C Jacobs; N Kyprianou
Journal:  Int J Cancer       Date:  1997-05-16       Impact factor: 7.396

2.  Genetic pattern of prostate cancer progression.

Authors:  T Saric; Z Brkanac; D A Troyer; S S Padalecki; M Sarosdy; K Williams; L Abadesco; R J Leach; P O'Connell
Journal:  Int J Cancer       Date:  1999-04-12       Impact factor: 7.396

3.  Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.

Authors:  M Stanbrough; I Leav; P W Kwan; G J Bubley; S P Balk
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

4.  Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.

Authors:  G Han; B A Foster; S Mistry; G Buchanan; J M Harris; W D Tilley; N M Greenberg
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

5.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

6.  A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model.

Authors:  Vasundara Venkateswaran; Laurence H Klotz; Meera Ramani; Linda M Sugar; Latha E Jacob; Robert K Nam; Neil E Fleshner
Journal:  Cancer Prev Res (Phila)       Date:  2009-04-28

7.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

8.  NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

Authors:  Ren Jie Jin; Yongqing Wang; Naoya Masumori; Kenichiro Ishii; Taiji Tsukamoto; Scott B Shappell; Simon W Hayward; Susan Kasper; Robert J Matusik
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

Authors:  X Li; V Placencio; J M Iturregui; C Uwamariya; A-R Sharif-Afshar; T Koyama; S W Hayward; N A Bhowmick
Journal:  Oncogene       Date:  2008-08-25       Impact factor: 9.867

Review 10.  Mesenchymal-epithelial interactions: past, present, and future.

Authors:  Gerald R Cunha
Journal:  Differentiation       Date:  2008-06-28       Impact factor: 3.880

View more
  49 in total

1.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Authors:  Michael A Augello; Deli Liu; Lesa D Deonarine; Brian D Robinson; Dennis Huang; Suzan Stelloo; Mirjam Blattner; Ashley S Doane; Elissa W P Wong; Yu Chen; Mark A Rubin; Himisha Beltran; Olivier Elemento; Andries M Bergman; Wilbert Zwart; Andrea Sboner; Noah Dephoure; Christopher E Barbieri
Journal:  Cancer Cell       Date:  2019-03-28       Impact factor: 31.743

2.  2,3,7,8-Tetrachlorodibenzo-p-dioxin has both pro-carcinogenic and anti-carcinogenic effects on neuroendocrine prostate carcinoma formation in TRAMP mice.

Authors:  Robert W Moore; Wayne A Fritz; Andrew J Schneider; Tien-Min Lin; Amanda M Branam; Stephen Safe; Richard E Peterson
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-03       Impact factor: 4.219

3.  δ-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice.

Authors:  Hong Wang; Xu Yang; Anna Liu; Guocan Wang; Maarten C Bosland; Chung S Yang
Journal:  Carcinogenesis       Date:  2018-02-09       Impact factor: 4.944

4.  [89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model.

Authors:  Kirstin A Zettlitz; Wen-Ting K Tsai; Scott M Knowles; Felix B Salazar; Naoko Kobayashi; Robert E Reiter; Anna M Wu
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

5.  Vitamin D Signaling Suppresses Early Prostate Carcinogenesis in TgAPT121 Mice.

Authors:  James C Fleet; Pavlo L Kovalenko; Yan Li; Justin Smolinski; Colleen Spees; Jun-Ge Yu; Jennifer M Thomas-Ahner; Min Cui; Antonio Neme; Carsten Carlberg; Steven K Clinton
Journal:  Cancer Prev Res (Phila)       Date:  2019-04-26

6.  USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair.

Authors:  Jennifer J McCann; Irina A Vasilevskaya; Neermala Poudel Neupane; Ayesha A Shafi; Christopher McNair; Emanuela Dylgjeri; Amy C Mandigo; Matthew J Schiewer; Randy S Schrecengost; Peter Gallagher; Timothy J Stanek; Steven B McMahon; Lisa D Berman-Booty; William F Ostrander; Karen E Knudsen
Journal:  Cancer Res       Date:  2019-11-18       Impact factor: 12.701

Review 7.  Clinical implications of PTEN loss in prostate cancer.

Authors:  Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

8.  Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.

Authors:  Claire M Faltermeier; Justin M Drake; Peter M Clark; Bryan A Smith; Yang Zong; Carmen Volpe; Colleen Mathis; Colm Morrissey; Brandon Castor; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

Review 9.  Metastases in Prostate Cancer.

Authors:  Federico La Manna; Sofia Karkampouna; Eugenio Zoni; Marta De Menna; Janine Hensel; George N Thalmann; Marianna Kruithof-de Julio
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 10.  The mouse prostate: a basic anatomical and histological guideline.

Authors:  Daniel S M Oliveira; Sijana Dzinic; Alan I Bonfil; Allen D Saliganan; Shijie Sheng; R Daniel Bonfil
Journal:  Bosn J Basic Med Sci       Date:  2016-02-10       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.